Litcius/Paper detail

Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

Shuofeng Yuan, Jasper Fuk‐Woo Chan, Kenn Ka-Hang Chik, Chris Chun-Yiu Chan, Jessica Oi‐Ling Tsang, Ronghui Liang, Jianli Cao, Kaiming Tang, Lin‐Lei Chen, Kun Wen, Jian‐Piao Cai, Zi‐Wei Ye, Gang Lu, Hin Chu, Dong‐Yan Jin, Kwok‐Yung Yuen

2020Pharmacological Research71 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)BexaroteneAbirateroneMedicinePharmacologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDrug approvalDrugVirologyChemistryInternal medicineProstate cancerCancerBiochemistryTranscription factorDiseaseInfectious disease (medical specialty)Nuclear receptorGeneOutbreakAndrogen receptorVitamin C and Antioxidants ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research